Cargando…
A modified live bat influenza A virus-based vaccine prototype provides full protection against HPAIV H5N1
Highly pathogenic avian influenza viruses (HPAIVs) of subtype H5 are a major threat for poultry holdings worldwide, here especially the zoonotic Asian H5N1 viruses. These HPAIVs have caused more than 500 fatal spillover infections from poultry to humans, with a looming danger of a new pandemic by es...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7229168/ https://www.ncbi.nlm.nih.gov/pubmed/32435514 http://dx.doi.org/10.1038/s41541-020-0185-6 |
_version_ | 1783534705487904768 |
---|---|
author | Schön, Jacob Ran, Wei Gorka, Marco Schwemmle, Martin Beer, Martin Hoffmann, Donata |
author_facet | Schön, Jacob Ran, Wei Gorka, Marco Schwemmle, Martin Beer, Martin Hoffmann, Donata |
author_sort | Schön, Jacob |
collection | PubMed |
description | Highly pathogenic avian influenza viruses (HPAIVs) of subtype H5 are a major threat for poultry holdings worldwide, here especially the zoonotic Asian H5N1 viruses. These HPAIVs have caused more than 500 fatal spillover infections from poultry to humans, with a looming danger of a new pandemic by establishing human-to-human transmissions. Besides culling measures in infected farms in endemic areas, vaccination is the major tool against HPAIV. However, the mainly used inactivated preparations have several limitations, like application to the individual animal by injection and a reduced efficiency. Here we present a modified live influenza vaccine prototype, which is based on the H17N10 bat influenza virus. The new chimeric vaccine strain R65(mono)/H17N10 was able to provide full protection against a lethal challenge infection with HPAIV H5N1 of juvenile and subadult chickens, as well as ferrets after oronasal immunization. In addition, the H5 vaccine prototype cannot reassort with avian influenza viruses and therefore is a promising tool against HPAIV H5 infection, allowing new vaccination strategies for efficient disease control. |
format | Online Article Text |
id | pubmed-7229168 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-72291682020-05-20 A modified live bat influenza A virus-based vaccine prototype provides full protection against HPAIV H5N1 Schön, Jacob Ran, Wei Gorka, Marco Schwemmle, Martin Beer, Martin Hoffmann, Donata NPJ Vaccines Article Highly pathogenic avian influenza viruses (HPAIVs) of subtype H5 are a major threat for poultry holdings worldwide, here especially the zoonotic Asian H5N1 viruses. These HPAIVs have caused more than 500 fatal spillover infections from poultry to humans, with a looming danger of a new pandemic by establishing human-to-human transmissions. Besides culling measures in infected farms in endemic areas, vaccination is the major tool against HPAIV. However, the mainly used inactivated preparations have several limitations, like application to the individual animal by injection and a reduced efficiency. Here we present a modified live influenza vaccine prototype, which is based on the H17N10 bat influenza virus. The new chimeric vaccine strain R65(mono)/H17N10 was able to provide full protection against a lethal challenge infection with HPAIV H5N1 of juvenile and subadult chickens, as well as ferrets after oronasal immunization. In addition, the H5 vaccine prototype cannot reassort with avian influenza viruses and therefore is a promising tool against HPAIV H5 infection, allowing new vaccination strategies for efficient disease control. Nature Publishing Group UK 2020-05-15 /pmc/articles/PMC7229168/ /pubmed/32435514 http://dx.doi.org/10.1038/s41541-020-0185-6 Text en © The Author(s) 2020 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Article Schön, Jacob Ran, Wei Gorka, Marco Schwemmle, Martin Beer, Martin Hoffmann, Donata A modified live bat influenza A virus-based vaccine prototype provides full protection against HPAIV H5N1 |
title | A modified live bat influenza A virus-based vaccine prototype provides full protection against HPAIV H5N1 |
title_full | A modified live bat influenza A virus-based vaccine prototype provides full protection against HPAIV H5N1 |
title_fullStr | A modified live bat influenza A virus-based vaccine prototype provides full protection against HPAIV H5N1 |
title_full_unstemmed | A modified live bat influenza A virus-based vaccine prototype provides full protection against HPAIV H5N1 |
title_short | A modified live bat influenza A virus-based vaccine prototype provides full protection against HPAIV H5N1 |
title_sort | modified live bat influenza a virus-based vaccine prototype provides full protection against hpaiv h5n1 |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7229168/ https://www.ncbi.nlm.nih.gov/pubmed/32435514 http://dx.doi.org/10.1038/s41541-020-0185-6 |
work_keys_str_mv | AT schonjacob amodifiedlivebatinfluenzaavirusbasedvaccineprototypeprovidesfullprotectionagainsthpaivh5n1 AT ranwei amodifiedlivebatinfluenzaavirusbasedvaccineprototypeprovidesfullprotectionagainsthpaivh5n1 AT gorkamarco amodifiedlivebatinfluenzaavirusbasedvaccineprototypeprovidesfullprotectionagainsthpaivh5n1 AT schwemmlemartin amodifiedlivebatinfluenzaavirusbasedvaccineprototypeprovidesfullprotectionagainsthpaivh5n1 AT beermartin amodifiedlivebatinfluenzaavirusbasedvaccineprototypeprovidesfullprotectionagainsthpaivh5n1 AT hoffmanndonata amodifiedlivebatinfluenzaavirusbasedvaccineprototypeprovidesfullprotectionagainsthpaivh5n1 AT schonjacob modifiedlivebatinfluenzaavirusbasedvaccineprototypeprovidesfullprotectionagainsthpaivh5n1 AT ranwei modifiedlivebatinfluenzaavirusbasedvaccineprototypeprovidesfullprotectionagainsthpaivh5n1 AT gorkamarco modifiedlivebatinfluenzaavirusbasedvaccineprototypeprovidesfullprotectionagainsthpaivh5n1 AT schwemmlemartin modifiedlivebatinfluenzaavirusbasedvaccineprototypeprovidesfullprotectionagainsthpaivh5n1 AT beermartin modifiedlivebatinfluenzaavirusbasedvaccineprototypeprovidesfullprotectionagainsthpaivh5n1 AT hoffmanndonata modifiedlivebatinfluenzaavirusbasedvaccineprototypeprovidesfullprotectionagainsthpaivh5n1 |